113 related articles for article (PubMed ID: 33035197)
1. Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer.
Mu Y; Wang D; Bie L; Luo S; Mu X; Zhao Y
Aging (Albany NY); 2020 Oct; 12(19):19585-19596. PubMed ID: 33035197
[TBL] [Abstract][Full Text] [Related]
2. Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.
Wang Y; Gao F; Jiang X; Zhao X; Wang Y; Kuai Q; Nie G; He M; Pan Y; Shi W; Ren S; Yu Q
J Biomed Nanotechnol; 2019 May; 15(5):966-978. PubMed ID: 30890228
[TBL] [Abstract][Full Text] [Related]
3. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy.
Qiu W; Zhang H; Chen X; Song L; Cui W; Ren S; Wang Y; Guo K; Li D; Chen R; Wang Z
Nanomedicine (Lond); 2019 Sep; 14(17):2339-2353. PubMed ID: 31414945
[No Abstract] [Full Text] [Related]
4. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
ACS Appl Mater Interfaces; 2024 May; ():. PubMed ID: 38813771
[TBL] [Abstract][Full Text] [Related]
6. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
[No Abstract] [Full Text] [Related]
7. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
8. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.
Qiu W; Chen R; Chen X; Zhang H; Song L; Cui W; Zhang J; Ye D; Zhang Y; Wang Z
Int J Nanomedicine; 2018; 13():6809-6827. PubMed ID: 30425490
[TBL] [Abstract][Full Text] [Related]
9. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
Frampton AE; Prado MM; López-Jiménez E; Fajardo-Puerta AB; Jawad ZAR; Lawton P; Giovannetti E; Habib NA; Castellano L; Stebbing J; Krell J; Jiao LR
Oncotarget; 2018 Apr; 9(27):19006-19013. PubMed ID: 29721179
[TBL] [Abstract][Full Text] [Related]
10. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
11. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
12. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
13. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
[TBL] [Abstract][Full Text] [Related]
14. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
16. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
[TBL] [Abstract][Full Text] [Related]
17. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo.
Li J; Di Y; Jin C; Fu D; Yang F; Jiang Y; Yao L; Hao S; Wang X; Subedi S; Ni Q
Nanoscale Res Lett; 2013 Apr; 8(1):176. PubMed ID: 23594566
[TBL] [Abstract][Full Text] [Related]
20. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
Hu W; Liu Q; Pan J; Sui Z
Biomed Pharmacother; 2018 Sep; 105():887-898. PubMed ID: 30021382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
